• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • SOD1 Therapies & Trials
      • T Regulatory Cell Therapies
      • Ulefnersen – Ionis Pharmaceuticals
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • Diagnostic Delay (in development)
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Meeting
    • Allied Professionals Forum
    • Alliance Webinars
    • ALS/MND Connect
    • Global Day Calendar
    • March of Faces
    • Patient Fellows Program
    • Global CRLI
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • Members
    • Member Registration
    • Forgot Password

Amylyx – AMX0035

Background

Amylyx Pharmaceuticals Inc. is a company that started in 2013 with the aim of testing a combination product called AMX0035 as a potential treatment for ALS and other neurodegenerative disorders. AMX0035 is an oral drug combining two compounds called sodium phenylbutyrate (PB) and tauroursodeoxycholic acid (TUDCA). TUDCA is also commonly referred to as taurursodiol (TURSO) or ursodoxicoltaurine, to learn more about TUDCA, please see here.

Trial Design & Results

AMX0035 was tested in a Phase 2/3 clinical trial called CENTAUR, which consisted of 137 participants recruited across 25 sites in the United States through the Northeast ALS (NEALS) Consortium. The trial was randomized, double-blind and placebo-controlled, and participants were assessed over a 24-week period for both safety and potential effect of AMX0035 on disease progression. The placebo-controlled trial was followed by an open label extension to collect further data from those that opted to participate.

The clinical trial had financial support from multiple key organizations in the ALS/MND field including The ALS Association, ALS Finding a Cure and the Northeast ALS Consortium (NEALS).

Results of the trial are published in The New England Journal of Medicine here. A press release delineated the key findings of the publication as follows:

  • Patients retained function longer on AMX0035 versus placebo; the study achieved its primary outcome of a difference on the Revised ALS Functional Rating Scale (ALSFRS-R).
  • AMX0035 demonstrated statistically significant benefit vs. placebo on the prespecified primary outcome (ALSFRS-R).
  • AMX0035 showed numerical benefits on secondary outcomes including measures of muscle strength, breathing, and hospitalizations.
  • AMX0035 was generally well tolerated with similar rates of adverse events recorded in the AMX0035 and placebo groups.

The publication further indicates that the effects were seen in addition to those provided by riluzole and edaravone use, though a better understanding of this additive value observation would benefit from further study. While the treatment was considered reasonably safe and tolerable, the publication also outlines that early gastrointestinal adverse events were notable and will need monitoring in future use.

An academic editorial was published (available here), outlining a cautious approach to interpreting the data while balancing that these results were indeed promising. The key points of the editorial are as follows:

  • Well-designed, multi-center trial with “tantalizing preliminary data.”
  • Trial was enriched for individuals with more rapidly progressive disease, making interpretation difficult for the wider population of people living with ALS/MND.
  • Secondary outcome measures were not convincingly aligned with the effect on ALSFRS-R.
  • Recommendation to proceed to a confirmatory phase 3 trial with wider eligibility criteria.

All participants in the trial (active drug and placebo) were also provided an option to enroll in an open-label extension where they would receive AMX0035. Data from this extension study was published in October 2020 in the journal Muscle & Nerve and demonstrated that individuals initially treated with AMX0035 lived an average of 6.5 months longer than those originally on placebo. This survival data was considered by some to strengthen the overall data. Two additional manuscripts on evaluation of survival were published here and here.

In 2021, Amylyx launched a 48-week, randomized placebo-controlled, confirmatory Phase 3 clinical trial called PHOENIX, which enrolled 664 participants across 55 sites in the first collaborative effort between TRICALS (Europe) and NEALS (US).

In March 2024, the company published a press release stating that this larger phase 3 trial confirmed that AMX0035 is generally safe. However, the study failed to confirm the results of the Phase 2/3 trial and did not meet its primary endpoint, defined as change from baseline in ALS Functional Rating ScaleRevised (ALSFRS-R) total score at 48 weeks. Additionally, no difference  between the treated and placebo groups was observed when looking at the secondary outcome measures including slow vital capacity measured both in clinic and remotely, and patient-reported outcomes and others. Amylyx also informed that when taking into consideration only those trial participants that had similar characteristics to the ones that took part in the CENTAUR trial, the results did not change.

Regulatory Submissions 

On November 2, 2021, following the positive results of the Phase 2/3 CENTAUR trial, Amylyx announced it had submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for AMX0035 and on December 29 it was announced as accepted for priority review. On March 30, 2022 an FDA Advisory Committee was convened to discuss and vote on whether they believed the current data established a conclusion that AMX0035 was effective in ALS; the result was a 6 – 4 ‘no’ vote. On July 5, the FDA announced it would reconvene the same Peripheral and Central Nervous System Drugs Advisory Committee (PCNDSAC) on September 7 for further discussion. Discussions focused on the additional analyses from the company’s clinical studies that were determined by the FDA to constitute a major amendment to the NDA. The second PCNDSAC vote was 7-2 in favor of sufficient evidence to support FDA approval. Of note, the ongoing Phase 3 clinical trial was cited throughout this discussion as an opportunity to seek confirmation of AMX0035 benefit in ALS and Amylyx verbally committed to removing the drug from market if approved and the second trial was negative. On September 29, 2022, the FDA approved AMX0035 as RELYVRIO based on the results of the Phase 2/3 trial and analyses from the open label extension.

On February 25, 2022, it was announced that the European Medicines Agency (EMA) agreed to review AMX0035 for potential approval. On May 30, 2023, it was shared by Amylyx that the Committee for Medicinal Products for Human Use (CHMP) was trending toward a negative opinion on a conditional Marketing Authorization for AMX0035. In June 2023 the European Medicine Agency (EMA) gave a negative opinion on AMX0035 based on the CENTAUR results. Amylyx asked for reconsideration and EMA gave a second negative opinion in October 2023, expressing  concerns regarding effective slowing of disease shown by AMX0035.

On June 13, 2022, it was announced that Health Canada approved AMX0035 as ALBRIOZA through the Notice of Compliance with Conditions (NOC/c) pathway where one of the conditions includes confirmation of safety and efficacy in the ongoing PHOENIX Phase 3 clinical trial. Canada became the first country anywhere in the world with regulatory approval of AMX0035.

In April 2024, given the PHOENIX topline results, Amylyx announced to be voluntarily discontinuing the marketing authorizations for RELYVRIO/ALBRIOZA in those countries where the drug had been approved (USA and Canada). The removal of the drug from the market, meant that RELYVRIO/ALBRIOZA would not be available for people affected by ALS, however, those who were taking the drug and wished to stay on it could still access it for free or through the open label extension phase of PHOENIX.

Additional Information 

a) TUDCA clinical trial: One of the compounds in AMX0035, TUDCA, was also evaluated in a phase 3 clinical trial alone with 336 participants across 9 sites in Europe supported by the TRICALS initiative. Results from this trial were released in March 2024. The study ran for 18 months and showed that TUDCA was safe and well tolerated but failed to meet its primary endpoint. Additionally, no difference was observed between the placebo or TUDCA treated groups in any of the secondary outcome measures. To learn more about TUDCA, please see here.

b) Sodium phenylbutyrate clinical trial: Sodium phenylbutyrate was evaluated in a small clinical trial by the NEALS consortium and published here in 2009. It was considered safe and tolerable but was not designed to determine an effect on disease progression. Both compounds have demonstrated some success at modifying disease course in preclinical animal  models.

Summary

It is the opinion of the Scientific Advisory Council (SAC) that there is sufficient evidence to conclude that at the studied dosage, AMX0035 did not show overall clinical benefit in individuals living with ALS. Furthermore, both sodium phenylbutyrate and TUDCA, while available by prescription and over-the-counter, respectively, also did not show clinical benefit in ALS.

International Alliance of ALS/MND Associations
September 2024


The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

  • Cath Muir

    Cath Muir
    Cath

  • Brian Parsons

    Brian Parsons

  • Dr Shelly Hoover

    Dr Shelly Hoover

  • Mark Miller

    Mark Miller

  • Xian-Zhang Niu, Diagnosed 2006 , Shaanxi ALS Association, China

    Xian-Zhang Niu, Diagnosed 2006 , Shaanxi ALS Association, China

  • Susan Anderson, Diagnosed 2014 , Hope Loves Company,  USA

    Susan Anderson, Diagnosed 2014 , Hope Loves Company, USA

  • Hanne Stenmose, Muskelsvindfonden, Denmark

    Hanne Stenmose, Muskelsvindfonden, Denmark

  • Fernando Ocampo Cardona, Colombia

    Fernando Ocampo Cardona, Colombia

  • H. Todd Kelly, Diagnosed 2013 , ALS Hope Foundation, USA

    H. Todd Kelly, Diagnosed 2013 , ALS Hope Foundation, USA

  • Ailsa Malcolm-Hutton, Diagnosed 2013,  MND Association of England, Wales and N Ireland

    Ailsa Malcolm-Hutton, Diagnosed 2013, MND Association of England, Wales and N Ireland

  • JP

    JP

  • Philip Brindle,  MND Association,  Diagnosed 2015,  England

    Philip Brindle, MND Association, Diagnosed 2015, England

  • João Marcos Andrietta, Diagnosed 2008 , ABrELA, Brazil

    João Marcos Andrietta, Diagnosed 2008 , ABrELA, Brazil

  • Enzo Maccarrone, AISLA ONLUS, Italy

    Enzo Maccarrone, AISLA ONLUS, Italy

  • Shay Rishoni, Diagnosed 2011 , Prize4Life, Israel

    Shay Rishoni, Diagnosed 2011 , Prize4Life, Israel

  • Andrea Zicchieri, Associazione conSLAncio Onlus, Italy

    Andrea Zicchieri, Associazione conSLAncio Onlus, Italy
    AndreaZicchieri_conSLAncioItaly

  • Marco Antonio Alvarez Mercado, Mexico

    Marco Antonio Alvarez Mercado, Mexico

  • Robbie Caliste, UK

    Robbie Caliste, UK

  • Shay Rishoni

    Shay Rishoni

  • Sharon Corosanite, Diagnosed 2014 , ALS Hope Foundation, USA

    Sharon Corosanite, Diagnosed 2014 , ALS Hope Foundation, USA

  • Jeff Sutherland

    Jeff Sutherland
    jspic

  • Jason Goodman, Les Turner ALS Foundation, USA

    Jason Goodman, Les Turner ALS Foundation, USA

  • IMG_1211

    IMG_1211

  • Den Haag, Diagnosed 2016 , The Netherlands

    Den Haag, Diagnosed 2016 , The Netherlands

  • Teddy Hanono Annie, Apoyo Integral Gila A.C., Diagnosed 2018, Mexico

    Teddy Hanono Annie, Apoyo Integral Gila A.C., Diagnosed 2018, Mexico

  • Dawn Morton, Diagnosed 2014 , MND Scotland, UK

    Dawn Morton, Diagnosed 2014 , MND Scotland, UK

  • Rolf Mauch, Association ALS Switzerland, Diagnosed 2015

    Rolf Mauch, Association ALS Switzerland, Diagnosed 2015

  • Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

    Soledad Rodriguez, FUNDELA, Diagnosed 2013, Spain

  • Sally Pauls, Diagnosed 2006 , Les Turner ALS Foundation

    Sally Pauls, Diagnosed 2006 , Les Turner ALS Foundation

  • Steven Spencer, Diagnosed 2014 , MND New Zealand

    Steven Spencer, Diagnosed 2014 , MND New Zealand

  • Ana Lilia RodriguezApoyo Integral Gila A.C., Diagnosed 2018, Mexico

    Ana Lilia RodriguezApoyo Integral Gila A.C., Diagnosed 2018, Mexico

  • Laurie Petit-Jean, Diagnosed 2012 , ARSLA, France

    Laurie Petit-Jean, Diagnosed 2012 , ARSLA, France

  • Irene McCaughey, Diagnosed 2011,  MND Australia

    Irene McCaughey, Diagnosed 2011, MND Australia

  • Fabio Carvalho, Associação Pró-Cura da ELA, Brazil

    Fabio Carvalho, Associação Pró-Cura da ELA, Brazil

  • David Solomon, Diagnosed 2015, MND Association of England, Wales and N Ireland

    David Solomon, Diagnosed 2015, MND Association of England, Wales and N Ireland

  • Carlos Alberto Báez Murillo, ACELA, Colombia

    Carlos Alberto Báez Murillo, ACELA, Colombia

  • Roxana Canova, Diagnosed 2012 ,  Asociación ELA Argentina

    Roxana Canova, Diagnosed 2012 , Asociación ELA Argentina

  • Jon Newsome, Les Turner ALS Foundation, USA

    Jon Newsome, Les Turner ALS Foundation, USA

  • Sam Hayden-Harler, Motor Neurone Disease (MND) Association, UK

    Sam Hayden-Harler, Motor Neurone Disease (MND) Association, UK

  • Carlos Alberto Arango, Colombia

    Carlos Alberto Arango, Colombia

  • Guoqiang Xu, Diagnosed 2016 , Shaanxi ALS Association, China

    Guoqiang Xu, Diagnosed 2016 , Shaanxi ALS Association, China

  • Liam Dwyer, England

    Liam Dwyer, England

  • Steve Lufkin, USA

    Steve Lufkin, USA
    IMG_3993

  • Steve Gallagher, ALS Society of Canada

    Steve Gallagher, ALS Society of Canada
    Picture1

  • Danny Reviers, Diagnosed 1979 , ALS Liga België, Belgium

    Danny Reviers, Diagnosed 1979 , ALS Liga België, Belgium

  • Mike Rannie,  ALS Canada,  Diagnosed 2017

    Mike Rannie, ALS Canada, Diagnosed 2017

  • Maria Lucia Wood Saldanha, Associação Pró-Cura da ELA, Brazil

    Maria Lucia Wood Saldanha, Associação Pró-Cura da ELA, Brazil

  • March of Faces Photo Submission_ALEX_ELA ARGENTINA

    March of Faces Photo Submission_ALEX_ELA ARGENTINA

  • Jon Newsome, USA

    Jon Newsome, USA

  • Catherine Pearce, Australia

    Catherine Pearce, Australia

Learn more about the March of Faces

Latest Tweets

  • Just now

Drugs No Longer in Development

  • Amylyx – AMX0035
  • Collaborative Medicinal Development – CuATSM
  • Cytokinetics – Reldesemtiv
  • Orphazyme – Arimoclomol
  • TUDCA Trial

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2025 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login